Alliancebernstein L.P. Trims Position in Haemonetics Co. (NYSE:HAE)

Alliancebernstein L.P. lowered its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 99,781 shares of the medical instruments supplier's stock after selling 8,564 shares during the quarter. Alliancebernstein L.P. owned 0.20% of Haemonetics worth $7,791,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Whittier Trust Co. purchased a new stake in shares of Haemonetics in the fourth quarter valued at approximately $62,000. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 240 shares during the period. AlphaQuest LLC grew its position in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares in the last quarter. KBC Group NV increased its stake in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after buying an additional 712 shares during the period. Finally, HighTower Advisors LLC raised its holdings in shares of Haemonetics by 7.8% in the fourth quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after acquiring an additional 244 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Remove Ads

Haemonetics Stock Down 1.9 %

Shares of HAE traded down $1.15 during mid-day trading on Tuesday, hitting $58.27. 572,832 shares of the company traded hands, compared to its average volume of 687,585. The company has a market capitalization of $2.93 billion, a PE ratio of 22.94, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The business has a 50 day moving average of $63.36 and a 200 day moving average of $73.29. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on HAE. Raymond James restated a "strong-buy" rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and dropped their target price for the company from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities reduced their price target on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. Barrington Research dropped their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, Needham & Company LLC reduced their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.